Canadian Trade Commissioner Service Features BioMark Diagnostics Next Generation Cancer Diagnostics

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

(TheNewswire)



   

Vancouver, British Columbia - TheNewswire – December 11th, 2019 – BioMark Diagnostics Inc. (“BioMark”) (CSE:BUX) (CNSX:BUX.CN) (FSE: 20B) (OTC:BMKDF) with the help of the Canadian Trade Commissioner Service (TCS) is developing dynamic global connections and undertaking research collaborations in an effort to bring its “next-generation” cancer diagnostics technology to market. BioMark is excited and proud to be featured in the official magazine of the Canadian Trade Commissioner Service (TCS) Life Sciences Special Edition. Please find below the link for the article on BioMark.

 

https://www.tradecommissioner.gc.ca/canadexport/0004195.aspx?lang=eng

 

The complete special edition report is available at https://www.tradecommissioner.gc.ca/canadexport/index.aspx?lang=eng

  

BioMark is very grateful of TCS and its CanExport Innovation (CXI) program. “The CXI program has been instrumental in funding and supporting our international market exploration to the United States, Japan and China. These are all important oncology related markets that we are targeting to introduce our cancer diagnostics solution”, says BioMark CEO and President Rashid Ahmed.”

  

About The CXI Program

 

The CXI program, formerly called Going Global Innovation, offers funding to support innovators from Canadian small and medium enterprises (SMEs), academic institutions and non-government research centres looking for foreign partners for the purpose of establishing collaborative research & development agreements. It helps companies offset a variety of costs to help innovators co-develop, validate or adapt their technologies, with the aim to commercialize.

  

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

 

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.

 

Company website: www.biomarkdiagnostics.com       

 

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779

Email: [email protected]  

 

Forward-Looking Information:

 

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark and its anticipated license arrangement.  Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

 

The CSE has not reviewed, approved or disapproved the content of this press release.

  

Copyright (c) 2019 TheNewswire - All rights reserved.